Topics

LIDDS develops its own proprietary product for intratumoral immunotherapy - Freedom to operate analysis done for the TLR9-agonist project

04:40 EDT 2 May 2019 | GlobalNewsWire (2014)
This article has expired, however you can still download the PDF.
Preview:
LIDDS has an ongoing preclinical development program based on a clinical stage TLR9 agonist. The objective is to use a NanoZolid® formulation with the TLR9 agonist as an intratumoral immunotherapy in combination with immune checkpoint inhibitor...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "LIDDS develops its own proprietary product for intratumoral immunotherapy - Freedom to operate analysis done for the TLR9-agonist project"

Quick Search

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...